长春高新：“三驾马车”驱动发展

Core Viewpoint - Changchun High-tech Industry (Group) Co., Ltd. is strategically positioning itself in the innovative and diversified upgrade of the domestic biopharmaceutical industry, focusing on three key areas: growth hormone, diversified commercialization of innovative products, and international licensing of new drugs [2][10]. Group 1: Innovation and R&D - Innovation is the lifeline for the survival and development of the company, with a strong emphasis on R&D investment and commercialization of innovative results [3][5]. - Changchun High-tech has established a comprehensive innovation system that spans R&D, production, clinical trials, and commercialization, particularly in the field of growth hormones [5][6]. - The company has made significant strides in the growth hormone market, breaking foreign monopolies and developing a complete product line, including the first injectable human growth hormone in China [4][6]. Group 2: Diversification Strategy - The company is transitioning from a reliance on a single product to a diversified innovation strategy to address market competition and internal structural challenges [6][8]. - Changchun High-tech is expanding its business into pediatric care, women's health, and oncology, developing a full-service system in these areas [7][8]. - The company is also enhancing its product pipeline through its subsidiaries, focusing on differentiated advantages and a variety of clinical trials [7][8]. Group 3: Internationalization Efforts - Internationalization is a core strategy for the company, aiming to build a competitive edge in the global biopharmaceutical market [9][10]. - The company has established a strategic framework for international collaboration, focusing on co-developing products that meet global market demands [9][10]. - Changchun High-tech plans to accelerate its internationalization process by issuing H-shares and listing in Hong Kong, enhancing its global competitiveness [10].